











Article

Perioperative Chemotherapy with FLOT Scheme in Resectable Gastric Adenocarcinoma: A Preliminary Correlation between TRG and Radiomics

Giovanni Maria Garbarino ¹, Marta Zerunian ², Eva Berardi ², Federico Mainardi ³, Emanuela Pillozzi ³, Michela Polici ², Gisella Guido ², Carlotta Rucci ², Tiziano Polidori ², Mariarita Tarallo ⁴, Giovanni Guglielmo Laracca ¹, Elsa Iannicelli ², Paolo Mercantini ¹, Bruno Annibale ⁵, Andrea Laghi ², and Damiano Caruso ^{2,*}

- ¹ Gastrointestinal Surgery Unit, Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Via di Grottarossa 1035-39, 00189 Rome, Italy; giovannimaria.garbarino@uniroma1.it (G.M.G.); giovanniguglielmo.laracca@uniroma1.it (G.G.L.); paolo.mercantini@uniroma1.it (P.M.)
 - ² Radiology Unit, Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Via di Grottarossa 1035-39, 00189 Rome, Italy; marta.zerunian@uniroma1.it (M.Z.); eva.berardi@uniroma1.it (E.B.); michela.polici@uniroma1.it (M.P.); gisella.guido@uniroma1.it (G.G.); carlotta.rucci@uniroma1.it (C.R.); tiziano.polidori@uniroma1.it (T.P.); elsa.iannicelli@uniroma1.it (E.I.); andrea.laghi@uniroma1.it (A.L.)
 - ³ Pathology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Via di Grottarossa 1035-39, 00189 Rome, Italy; federico.mainardi@uniroma1.it (F.M.); emanuela.pillozzi@uniroma1.it (E.P.)
 - ⁴ Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Policlinico Umberto I Hospital, Via Giovanni Maria Lancisi, 2, 00161 Roma, Italy; mariarita.tarallo@uniroma1.it
 - ⁵ Gastroenterology Unit, Department of Medical Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Via di Grottarossa 1035-39, 00189 Rome, Italy; bruno.annibale@uniroma1.it
- * Correspondence: damiano.caruso@uniroma1.it; Tel.: +39-06-3377-5691



Citation: Garbarino, G.M.; Zerunian, M.; Berardi, E.; Mainardi, F.; Pillozzi, E.; Polici, M.; Guido, G.; Rucci, C.; Polidori, T.; Tarallo, M.; et al. Perioperative Chemotherapy with FLOT Scheme in Resectable Gastric Adenocarcinoma: A Preliminary Correlation between TRG and Radiomics. *Appl. Sci.* **2021**, *11*, 9211. <https://doi.org/10.3390/app11199211>

Academic Editor: Francesco Bianconi

Received: 4 September 2021

Accepted: 24 September 2021

Published: 3 October 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Featured Application: Radiomics may be a useful non-invasive biomarker in the assessment of response to perioperative chemotherapy in gastric cancer patients.

Abstract: Perioperative chemotherapy (p-ChT) with a fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) scheme is the gold standard of care for locally advanced gastric cancer. We aimed to test CT radiomics performance in early response prediction for p-ChT. Patients with advanced gastric cancer who underwent contrast enhanced CT prior to and post p-ChT were retrospectively enrolled. Histologic evaluation of resected specimens was used as the reference standard, and patients were divided into responders (TRG 1a-1b) and non-responders (TRG 2-3) according to their Becker tumor regression grade (TRG). A volumetric region of interest including the whole tumor tissue was drawn from a CT portal-venous phase before and after p-ChT; 120 radiomic features, both first and second order, were extracted. CT radiomics performances were derived from baseline CT radiomics alone and Δ Radiomics to predict response to p-ChT according to the TRG and tested using a receiver operating characteristic (ROC) curve. The final population comprised 15 patients, 6 (40%) responders and 9 (60%) non-responders. Among pre-treatment CT radiomics parameters, *Shape*, *GLCM*, *First order*, and *NGTDM* features showed a significant ability to discriminate between responders and non-responders ($p < 0.011$), with *Cluster Shade* and *Autocorrelation* (*GLCM* features) having $AUC = 0.907$. Δ Radiomics showed significant differences for *Shape*, *GLRLM*, *GLSZM*, and *NGTDM* features ($p < 0.007$). *MeshVolume* (*Shape* feature) and *LongRunEmphasis* (*GLRLM* feature) had $AUC = 0.889$. In conclusion, CT radiomics may represent an important supportive approach for the radiologic evaluation of advanced gastric cancer patients.

Keywords: radiomics; gastric cancer; perioperative chemotherapy; response to treatment

1. Introduction

Gastric cancer is one of the most common malignant tumors, and it ranks third worldwide in terms of mortality rates. Recently, with the increased progress in treatment approaches, patients with pathological stage I disease have achieved a cure rate of 90%; nevertheless, the prognosis of advanced gastric cancer is still poor in Europe, and the 5-year survival rate is reported to be about 25% [1,2]. Radical gastrectomy with D2 lymphadenectomy has historically been the milestone treatment for locally advanced gastric cancer (Stage IB-III) [3,4]. Since the publication of the MAGIC trial results showing that three preoperative and three postoperative cycles of epirubicin, cisplatin, and fluorouracil (ECF) improves progression-free and overall survival, the use of perioperative chemotherapy (p-ChT) has spread throughout Western countries [5]. Currently in Europe, the gold standard treatment for patients with locally advanced gastric cancer is radical gastrectomy with D2 lymphadenectomy and p-ChT with fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) [6].

The present trial compared the perioperative docetaxel-based triplet FLOT with an anthracycline-based triplet of either ECF or ECX (epirubicin, cisplatin, and capecitabine) for patients with resectable gastric or esophagogastric junction adenocarcinoma. The results of the trial showed that the patients treated with FLOT achieved a significantly higher rate of pathological complete regression (16% vs. 6%; $p = 0.02$) associated with an improved overall survival with an estimated advantage of 15 months (50 vs. 35 months; $p = 0.012$) when compared to the ECF/ECX group. However, not all patients are responders who can benefit from this approach. In non-responder patients, costly and ineffective preoperative chemotherapy could be avoided if they are assessed beforehand [7–9]. Currently, the only objective method of determining whether a patient has responded to preoperative chemotherapy is the evaluation of the tumor regression grade (TRG) of a surgical specimen. In order to exclude non-responder patients from preoperative chemotherapy, a diagnostic method to discriminate responder and non-responder patients should be identified at the time of the diagnosis.

Radiomics is a tool able to extract ultrastructural quantitative data from previously acquired medical images (e.g., computed tomography, magnetic resonance imaging, ultrasound), providing features that characterize the spatial relationships of signal intensities in a specific tissue (e.g., a tumoral lesion) [10]. Radiomics has already demonstrated its usefulness in predicting treatment response across a range of cancer types and imaging modalities [10–15]. Regarding gastric cancer, CT radiomics has already been shown to be a promising preoperative non-invasive prognostic biomarker [16]. Pre-treatment radiomics extracted from a baseline CT examination could also be used to provide important information about the response rate to preoperative chemotherapy for gastric cancer. This would improve patients' chances of selection for multimodal treatment [17,18]. Therefore, radiomics may represent an innovative non-invasive biomarker for the response to perioperative chemotherapy in locally advanced gastric cancer. Thus, the aim of this study is to assess the performance of CT radiomics in predicting the response to perioperative chemotherapy with a FLOT regimen in gastric cancer patients.

2. Materials and Methods

2.1. Study Population

The current retrospective observational study regards all patients undergoing surgery for gastric cancer at the Gastrointestinal Surgery Unit of Sant'Andrea University Hospital between January 2019 and November 2020. The study was conducted in accordance with the Declaration of Helsinki and its later amendments. Formal Institutional Review Board approval was not required due to the non-interventional, retrospective nature of the study. All patients provided signed consent for data treatment and analysis for scientific purposes before any procedures.

Data were registered in a prospectively maintained database of all patients undergoing gastric resection with perioperative chemotherapy for gastric cancer. The following

data were included in the study: demographics (age, sex, ASA score, BMI, comorbidities), characteristics of the tumoral lesion and its pathology, and baseline and post-perioperative chemotherapy CT examinations. The following inclusion criteria were considered: (1) having previously undergone a gastrectomy with a histologically proven diagnosis of gastric carcinoma with baseline staging CT scan pre- and post-perioperative chemotherapy and a multidisciplinary team evaluation; (2) preoperative tumor stage as follows: cT2-T4a, cN0-N3, or M0; (3) age > 18 years old; and (4) having undergone perioperative chemotherapy with docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT). The exclusion criteria were: (1) unavailability of both baseline and post-perioperative chemotherapy CT examinations; (2) disease progression (metastatic tumoral spread) during perioperative chemotherapy not eligible for further surgery; and (3) the use of a different chemotherapy scheme than FLOT.

Patients were divided into two groups following the Becker TRG classification system: non-responders (TRG 1a-1b) and responders (TRG 2-3) [19–21]. Tumor staging was evaluated according to the American Joint Committee on Cancer (AJCC) Staging System, 8th edition [20]. All patients underwent a total body CT scan and endoscopic ultrasound for preoperative clinical staging, and the clinical pathway was determined by the multidisciplinary team (MDT).

2.2. CT Acquisition Protocol

Each patient with a histological diagnosis of gastric cancer underwent a pre- and post-p-ChT total body CT scan with contrast medium injection. CT scans were acquired on 128-slice CT (GE Revolution EVO Slice CT Scanner, GE Medical Systems, Milwaukee, WI, USA) in supine position, at end-inspiration and with cranio-caudal scanning. For the unenhanced imaging, arterial and delayed phase Z-axis coverage included the diaphragm apex to the iliac bone, and the portal-venous phase was scanned from the supraclavicular space to the pubic symphysis. For the purposes of this study, only the portal-venous phase was assessed.

All patients underwent gastric lumen distention by drinking 4 glasses (125 mL) of water directly before the CT image acquisition. Contrast medium intravenous injection was tailored for each patient according to lean body weight (LBW): each patient received 0.7 gI/kg LBW [22,23] and the result divided by contrast medium concentration (mgI/mL) obtaining the volume of administration. Iso-osmolar non-ionic contrast medium (iodixanol 320 mgI/mL, Visipaque 320; GE Healthcare, Cork, Ireland) was administered through an 18–20 gauge antecubital intravenous access, followed by 40 mL of saline solution with a contrast media injection system (Medrad® Centargo, Bayer) with a flow rate of 3 mL/s. Post-contrast CT scan timing was based on the bolus-tracking method (Smart Prep, GE, Milwaukee, WI, USA) by placing a 150 HU-threshold region of interest (ROI) within the lumen of the abdominal aorta at the celiac tripod level. The late arterial phase (18 s after threshold reached), portal-venous phase (70 s after the threshold reached), and delayed phase (180 s after threshold reached) were performed for each patient's unenhanced phase.

CT technical parameters were: tube voltage 100 kV; tube current modulation was applied by using SMART mA (GE Healthcare, Milwaukee, WI, USA) ranging from 130 to 300 mAs; spiral pitch factor 0.98; section collimation 64 × 0.625 mm; rotation time 0.6 s. All CT images were reconstructed with slice thickness of 1.25 mm with standard soft tissue reconstruction, by applying iterative reconstruction at 50% (ASiR-V, GE Healthcare, Milwaukee, WI, USA). No other iterative reconstruction was analyzed [24].

2.3. Image Segmentation Analysis

CT examinations were retrospectively analyzed in consensus by two radiologists (EB and DC, with 5 and 10 years of experience in abdominal oncology, respectively). For each patient, both the baseline and post-p-ChT CT scans were analyzed by volumetric tumor segmentation using 3D Slicer software (version 4.10.2, <http://www.slicer.org>, accessed on 24 October 2020) that had already been tested on gastric neoplasms [17,25]. The volumetric

region of interest (VOI) was manually outlined slice-by-slice on portal-venous phase contrast-enhanced CT examinations to cover the entire gastric cancer area while avoiding the inclusion of surrounding healthy mucosa, gas, and perigastric fat in the analysis.

2.4. Radiomics Features Extraction

Radiomics features were extracted from the VOIs using a dedicated 3D Slicer radiomics extension (pyradiomics library, [26]), as shown in Figure 1. No spatial filter alteration scaling was applied to the radiomic features. In particular, several radiomics features of the first and second order were extracted as follows: (a) first-order statistics (19 features), (b) 2D and 3D shape-based features (26 features), (c) gray level co-occurrence matrix (GLCM, 24 features), (d) gray level run length matrix (GLRLM, 16 features), (e) gray level size zone matrix (GLSZM, 16 features), (f) neighboring gray tone difference matrix (NGTDM, 5 features), and (g) gray level dependence matrix (GLDM, 14 features). From baseline and post-pChT CT images, a total of 120 radiomic features were extracted. Additionally, a Δ Radiomics number was obtained using the following formula:

$$\Delta\text{Radiomics} = \text{Radiomics}_{\text{Post-CHT}} - \text{Radiomics}_{\text{Pre-CHT}}$$




Figure 1. A volumetric manual segmentation performed with 3D Slicer software (version 4.10.2, <http://www.slicer.org> (accessed on 24 October 2020)) on a portal-venous phase CT scan of a 78-year-old woman with locally advanced gastric cancer after perioperative chemotherapy. (a–c) Axial, coronal, and sagittal plane views respectively. (d) The final 3D representation of the whole tumor segment, avoiding the surrounding healthy mucosa, gas, and perigastric fat.

2.5. Statistical Analysis

Continuous data were expressed as the mean \pm standard deviation. Differences in continuous parametric variables were compared using the unpaired Student's *t* test, and the Mann–Whitney U test was used for the continuous nonparametric variables. The categorical variables were expressed by numbers and percentages and their comparisons were calculated with the χ^2 test or Fisher's exact test with or without Yates correction. Our hypothesis test for all the comparisons performed considered H_0 as no differences between responders and non-responders while H_1 represented the presence of differences between the two groups.

The diagnostic performance of radiomic features extracted from baseline CT scans to differentiate responder from non-responder patients was assessed using the receiver operating curve (ROC), calculating area under the curve (AUC), sensitivity, specificity, and accuracy. The diagnostic performance of Δ Radiomics was assessed with ROC curve analysis. Significance was defined as $p < 0.05$. Statistical analysis was performed using the SPSS 25.0 (SPSS, Inc., Chicago, IL, USA) and MedCalc software (MedCalc Software, version15, Ostend, Belgium).

3. Results

3.1. Study Population

Between January 2019 and November 2020, a total of 48 patients underwent a gastrectomy with perioperative chemotherapy for gastric adenocarcinoma at our institution. Twenty-seven patients who underwent chemotherapy regimens other than FLOT, two patients without available pre- and post-perioperative chemotherapy CT scans, and four patients who had their radiological disease progression assessed with CT scans after perioperative FLOT therapy were excluded from the study. Fifteen patients fulfilling the study criteria were included in the study. Patients were divided into two groups: 9 (60%) non-responders to p-ChT (TRG1a-1b) and 6 (40%) responders to p-ChT (TRG2-3) (Figure 2).




Figure 2. Enrollment population flowchart with inclusion and exclusion criteria and the final enrolled population.

3.2. Demographic Characteristics

No significant differences were observed between the two groups concerning the demographic characteristics age, sex, body mass index (BMI), American Society of Anesthesiology (ASA) score, comorbidities, and tumor histotype and location (Table 1). A non-significant trend of larger tumors was observed in the non-responder group (2.2 ± 0.8 cm vs. 3.4 ± 1.1 cm; $p = 0.073$). Ten patients underwent subtotal gastrectomy (30%; $p = 0.264$) and 5 patients underwent a total gastrectomy (60%; $p = 0.264$). Six patients were treated by open approach (66.7%; $p = 0.237$) and nine patients by laparoscopy (22.2%; $p = 0.237$). Postoperative morbidity occurred more frequently in the non-responder group (14.3%; $p = 0.170$), and 30-day mortality was zero in both groups.

Table 1. Baseline characteristics of the included patients.

	Responders <i>n</i> = 6	Non-Responders <i>n</i> = 9	<i>p</i>
Age (years, mean \pmSD)	59.9 (\pm 12.6)	64.8 (\pm 15.2)	0.224
Gender F/M	3/3	3/6	0.519
BMI (mean, \pmSD)	23.8 (\pm 2.2)	24.8 (\pm 3.1)	0.639
ASA (n, %)			0.174
1	0 (0.0%)	1 (11.1%)	
2	3 (50.0%)	2 (22.2%)	
3	3 (50.0%)	6 (66.6%)	
4	0 (0.0%)	0 (0.0%)	
Comorbidities (n, %)	3 (50.0%)	4 (44.4%)	0.408
Histotype			0.274
Non poorly cohesive	3 (50.0%)	6 (66.6%)	
Poorly cohesive	2 (33.3%)	0 (0.0%)	
Poorly cohesive, signet-ring cell	0 (0.0%)	1 (11.1%)	
Mixed	1 (16.7%)	2 (22.2%)	
Tumor Location			0.255
Cardias	1 (16.7%)	0 (0.0%)	
Subcardial	1 (16.7%)	1 (11.1%)	
Fundus	0 (0.0%)	0 (0.0%)	
Body	0 (0.0%)	1 (11.1%)	
Angulus	2 (33.3%)	1 (11.1%)	
Antrum	1 (16.7%)	6 (66.7%)	
Pylorus	1 (16.7%)	0 (0.0%)	
Tumor size (cm, mean \pmSD)	2.2 (\pm 0.8)	3.4 (\pm 1.1)	0.073

Body mass index (BMI), American Society of Anesthesiology (ASA).

3.3. Pathological and Long-Term Oncological Outcomes

Pathological examination of the resected specimens showed comparable T stages ($p = 0.315$), N stages ($p = 0.397$), number of retrieved lymph nodes (26.0 vs. 24.2; $p = 1.000$), and number of positive nodes between groups ($p = 0.388$). Furthermore, R0 resection was achieved in 100% of cases in both groups ($p = 1.000$). Finally, post-preoperative TNM stage was comparable between the groups ($p = 0.774$). Results are listed in Table 2.

Table 2. Oncological outcomes including ypTNM stage, resection margin, node details, and lymphovascular/perineural invasion in responder vs. non-responder patients.

	Responders <i>n</i> = 6	Non- Responders <i>n</i> = 9	<i>p</i>
T-stage (n, %)			0.315
ypT1	3 (50.0%)	2 (22.2%)	
ypT2	1 (16.7%)	3 (33.3%)	
ypT3	1 (16.7%)	4 (44.4%)	
ypT4a	1 (16.7%)	0 (0.0%)	
ypT4b	0 (0.0%)	0 (0.0%)	
N-stage (n, %)			0.397
ypN0	5 (83.3%)	4 (44.4%)	
ypN1	0 (0.0%)	1 (11.1%)	
ypN2	0 (0.0%)	2 (22.2%)	
ypN3	1 (16.7%)	2 (22.2%)	
M-stage (n, %)			1.000
ypM0	6 (100%)	9 (100%)	
ypM1	0 (0.0%)	0 (0.0%)	

Table 2. Cont.

	Responders <i>n</i> = 6	Non- Responders <i>n</i> = 9	<i>p</i>
R0 resection (n, %)	6 (100%)	9 (100%)	1.000
Retrieved nodes (mean ±SD)	26.0 (±10.5)	24.2 (±7.3)	1.000
Positive nodes (mean ±SD)	2.7 (±6.5)	3.4 (±3.9)	0.388
Node ratio (mean ±SD)	0.1 (±0.3)	0.1 (±0.1)	0.388
Lymphovascular invasion (n, %)	2 (33.3%)	4 (44.4%)	1.000
Perineural invasion (n, %)	1 (16.7%)	3 (33.3%)	0.604
ypTNM stage (n, %)			0.774
yI	3 (50.0%)	3 (33.3%)	
yII	2 (33.3%)	4 (44.4%)	
yIII	1 (16.7%)	1 (11.1%)	
yIV	0 (0.0%)	1 (11.1%)	

3.4. Radiomics Features Extraction

Radiomics features of pre-p-ChT CT examinations showed significant differences between responders and non-responders for *Shape*, *GLCM*, *First order*, and *NGTDM* features. In particular, the extracted radiomics parameters showed significant differences in *LeastAxisLength* (*Shape* feature; $p = 0.017$), *Cluster Shade* and *Autocorrelation* (*GLCM* features; $p = 0.007$ and 0.005 , respectively), *Skewness* (*First order* feature; $p = 0.012$), and *Strength* (*NGTDM* feature; $p = 0.049$). The diagnostic performance of these features was tested with ROC curves showing AUCs of 0.815 for *LeastAxisLength*, AUC of 0.907 for both *Cluster Shade* and *Autocorrelation*, an AUC of 0.889 for *Skewness*, and an AUC of 0.815 for *Strength* (all $p < 0.011$). Complete results are shown in Table 3 and Figure 3.

Table 3. Pre-p-ChT radiomics analysis between responders and non-responders expressed as simple comparison analysis (Student's *t* test/Mann–Whitney U) and the receiver operating characteristic (ROC) curve analysis with the area under the curve (AUC), sensitivity, specificity, and interclass coefficient (IC).

Features (±SD)		Student's <i>t</i> Test/Mann–Whitney U			ROC Curve Analysis				
		Responders	Non-Responders	<i>p</i>	AUC	Sensibility	Specificity	95%CI	<i>p</i>
<i>Shape</i>	<i>LeastAxisLength</i>	40,710,033,491,504,200 (±10,571,464,896,142,900)	25,790,429,154,707,500 (±10,255,032,505,952,900)	0.017	0.815	88.89%	66.67%	0.53–0.96	0.011
<i>GLCM</i>	<i>Cluster Shade</i>	0.386 (±0.268)	146,046,470,600.51 (±221,971,036,175.30)	0.007	0.907	66.67%	100%	0.64–0.99	<0.0001
	<i>Autocorrelation</i>	600,512,843,926.50 (±266,967,395,651.26)	172,336,715,286.11 (±225,325,689,588.11)	0.005	0.907	88.89%	83.33%	0.64–0.99	<0.0001
<i>First order</i>	<i>Skewness</i>	−41,087,393,947.19 (±92,868,722,144.65)	−266,130,994,643.65 (±242,387,476,528.67)	0.012	0.889	88.89%	83.33%	0.62–0.99	<0.0001
<i>NGTDM</i>	<i>Strength</i>	0.099 (±0.065)	12,828,807,550.54 (±38,486,422,650.55)	0.049	0.815	55.56%	100%	0.53–0.96	0.007

ΔRadiomics values showed significant differences between responders and non-responders for *Shape*, *GLRLM*, *GLSZM*, and *NGTDM* features. Specific features include *MeshVolume*, *LeastAxisLength*, and *SurfaceVolume* (*Shape* features; $p = 0.012$, 0.036 , and 0.020 respectively); *LongRunEmphasis* (*GLRLM* feature; $p = 0.039$); *LargeAreaLowGrayLevelEmphasis* (*GLSZM* feature; $p = 0.017$); and *Contrast* (*NGTDM* feature; $p = 0.049$). Further, ROC curve analysis showed significant results for the abovementioned ΔRadiomics features with an AUC of 0.889 for *MeshVolume*, 0.833 for *LeastAxisLength*, 0.852 for *SurfaceVolume*, 0.889 for *LongRunEmphasis*, 0.833 for *LargeAreaLowGrayLevelEmphasis*, and 0.796 for *Contrast* (all $p < 0.007$). Full results including sensitivity, specificity, and confidence interval (CI) are reported in Table 4 and Figure 4.




Figure 3. Significant receiver operating characteristic (ROC) curves of the radiomic features extracted from pre-perioperative chemotherapy CT scans. The area under the curve (AUC) and *p*-value are reported in each ROC curve. The best AUC achieved is represented by *Cluster Shade* and *Autocorrelation*.

Table 4. ΔRadiomics analysis between responders and non-responders expressed as a simple comparison analysis (Student’s *t* test/Mann–Whitney U) and receiver operating characteristic (ROC) curve analysis with the area under the curve (AUC), sensitivity, specificity, and 95% confidence interval (95%CI).

Features (±SD)	Student’s <i>t</i> Test/Mann–Whitney U			ROC Curve Analysis				
	Responders	Non-Responders	<i>p</i>	AUC	Sensitivity	Specificity	95%CI	<i>p</i>
<i>MeshVolume</i>	47,726,724,383.33 (±11682656826.61)	13,076,118.00 (±30921508.47)	0.012	0.889	66.67%	100%	0.62–0.99	<0.0001
<i>Shape</i> <i>LeastAxisLength</i>	12,285,531,715,430,500 (±14137871167552600)	5,973,056,305,063,620 (±249,77,695,721,154,400)	0.036	0.833	77.78%	100%	0.55–0.97	0.0045
<i>SurfaceVolume</i>	0.014 (±0.05200651)	0.1233 (±0.089998892)	0.020	0.852	88.89%	83.33%	0.57–0.97	0.0021
<i>GLRLM</i> <i>LongRunEmphasis</i>	2,579,499,151,841.67 (±3.283)	149,429,893,302.00 (±1.43237)	0.039	0.889	66.7%	100%	0.62–0.99	<0.0001
<i>GLSZM</i> <i>LargeAreaLowGray-LevelEmphasis</i>	408,041,364,296.00 (±3.38877)	36,590,288,676.44 (±1.9542)	0.017	0.833	100%	66.67%	0.55–0.97	0.007
<i>NGTDM</i> <i>Contrast</i>	0.00000 (±0.00571308)	0.01000 (±0.00986065)	0.049	0.796	66.67%	83.33%	0.53–0.96	0.005




Figure 4. Significant receiver operating characteristic (ROC) curves of Δ Radiomics obtained from the differences between pre-perioperative chemotherapy CT and post-perioperative chemotherapy CT. The area under the curve (AUC) and the p -value are reported in each ROC curve. The best AUC achieved is represented by *MeshVolume* and *LongRunEmphasis* features.

4. Discussion

Our results showed significant performances from pre-p-ChT radiomics and Δ Radiomics in differentiating between responder and non-responder patients with gastric cancer treated with a FLOT regimen before surgery. The best performance for pre-p-ChT radiomics showed an AUC of 0.907 for *Cluster*, *Shade*, and *Autocorrelation* (GLCM features) with sensitivity of 66.67% and 88.89% and specificity of 100% and 83.33%, respectively (all $p < 0.0001$). Additionally, Δ Radiomics showed interesting results in terms of diagnostic performance with the best ROC curve showing an AUC = 0.889 for *MeshVolume* (*Shape* feature) and for *LongRunEmphasis* (GLRLM feature), with sensitivity and specificity of 66.67% and 100% for both (all $p < 0.0001$). Up to now, only a few studies have assessed the role of radiomics in the prediction of response to perioperative or neoadjuvant chemotherapy [17,27–29]. To the best of our knowledge, no CT radiomics studies predicting the response to perioperative chemotherapy with a FLOT regimen in gastric cancer patients have been performed.

The potential of radiomics in the early identification of perioperative treatment response represents a great opportunity for developing treatment strategies. Neoadjuvant chemotherapy responders showed an improvement in survival after gastrectomy [27]. The possibility of the early identification of non-responder patients would allow a differently tailored therapeutic strategy.

Different aspects of gastric cancer disease and radiomics have been investigated in several studies, which have included correlations with histological grade [28], staging, and therapeutic outcome [29–33]. As mentioned above, some studies have reported interesting results in response to neoadjuvant chemotherapy assessment. In particular, Giganti and colleagues performed pre-neoadjuvant ChT radiomics on 34 gastric cancer patients, cor-

relating the extracted features with TRG. Their results indicated that three pre-treatment radiomic parameters (*Entropy*, *Root Mean Square*, and *Range*) have a possible predictive value in the discrimination between responders and non-responders in patients naïve for treatment.

Discrepancies with our study in terms of different significant radiomic features could be related to the small population sample and to their use of filtered radiomics that enhance some features more than others. Another interesting study performed by Li Z. et al. assessed the role of radiomics in the response to neoadjuvant chemotherapy prediction. The authors enrolled 30 patients and performed radiomics on pre-treatment CT on both arterial and portal-venous phases. Results showed how portal-venous phase radiomics performed better than arterial phase radiomics in the prediction of TRG, with an AUC of 0.72 compared to one of 0.60 [17]. These results are important in terms of radiomics application due to the increased availability of portal-venous phase in comparison to arterial phase in oncologic studies, and this reinforced our decision to test radiomics on the portal-venous phase, even though more data are needed for confirmation.

Moreover, Sun K-Y. et al. performed a combined multivariate analysis on 106 patients divided into training and validation cohorts. The researchers proposed a RAD score selected by the randomized decision tree method, and then integrated it into a RAD clinical score. Results showed how RAD score alone showed the best performance in assessing response to neoadjuvant ChT compared to RAD clinical score and clinical score only (AUC 0.82 vs. 0.70 and 0.62 respectively). Their study identified 25 radiomic features significantly related to response to neoadjuvant chemotherapy including *GLCM* and *GLRLM*, with more than half of the features belonging to the latter group [30]. Our study found ten radiomic features (five for each analysis performed); among these features, *GLCM* and *GLRLM* showed interesting results. *GLCM* and *GLRLM* are features expressing the signal heterogeneity within a lesion. They represent the relative relationship between the distribution and location of the gray level. In general, these features (*GLCM* and *GLRLM*) are more pronounced in patients with lack of response to neoadjuvant chemotherapy. They are possible expressions of the more pronounced intra-tumoral heterogeneity in non-responders than responders. The *Cluster Shade* represents a measure of the skewness and uniformity of the *GLCM*, and *Autocorrelation* expresses the magnitude of the fineness or coarseness of a lesion's texture. Although our results regarding *Cluster Shade* are in line with this trend, *Autocorrelation* showed the opposite trend and further investigation is needed to explore this. Among *GLRLM* features, *LongRunEmphasis*, a measure of the distribution of long run lengths, showed greater value, longer run lengths, and more coarse structural textures. Our Δ Radiomics for this feature showed that responders had a wider delta compared to non-responders. This is explicable with a reduced *LongRunEmphasis* after p-ChT in responders. As already reported in many studies conducted on different tumor types, the heterogeneity of radiomics features is greater in more aggressive tumors in terms of proliferation, angiogenesis, and metastatic spread. These characteristics have often resulted in chemotherapy resistance [31,32].

The Δ Radiomics data of our study are also in line with a study performed by Mazzei et al. [33]. The study authors analyzed Δ Radiomics on pre-ChT in 23 advanced gastric cancer patients. On multivariate analysis, their results showed a significant correlation between the delta *GLCM Contrast* features and complete pathological response. Additionally, our analysis showed how *Contrast* features have good diagnostic ability in differentiating responders from non-responders.

Despite the interesting results, our study has some limitations, as follows: (a) the small cohort of patients made it impossible to perform training and validation for sub-groups and led to possible instability of the results; (b) the lack of multivariate analysis with clinical and radiological findings; (c) the lack of correlation with histologic and molecular expressions of the tumor; (d) the lack of radiomics analysis on the arterial phase; (e) the lack of different iterative reconstruction levels applied to CT acquisition that might alter radiomic features (we applied fixed iterative reconstruction percentages to avoid bias since

this aspect was beyond the aim of the study); and finally (f) the manual segmentation of the whole gastric tumor.

5. Conclusions

Our preliminary results suggest the potential role of radiomics in the assessment of response to perioperative chemotherapy in gastric cancer patients. This new non-invasive imaging biomarker could be integrated into the comprehensive evaluation of gastric cancer patients to provide an early assessment of patient response to chemotherapy and provide improved therapeutic management. However, further investigations are needed to confirm the data before they are given full consideration in the clinical setting.

Author Contributions: Conceptualization, G.M.G., M.Z., D.C. and A.L.; methodology, G.M.G. and D.C.; software, M.Z. and E.B.; validation, F.M., E.P. and G.G.L.; formal analysis, M.Z., E.B. and D.C.; investigation, M.P., G.G. and T.P.; resources, E.P. and B.A.; data curation, P.M., M.T., F.M. and G.G.L.; writing—original draft preparation, M.Z., M.T. and C.R.; writing—review and editing, G.M.G., E.I., P.M. and D.C.; visualization, P.M. and G.G.L.; supervision, A.L., B.A. and D.C.; project administration, B.A. and A.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. Formal Institutional Review Board approval was not required because of the non-interventional retrospective design; however, signed consent for the treatment and the analysis of data for scientific purposes was obtained from all patients before any procedure was performed.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient(s) to publish this paper.

Data Availability Statement: Data supporting results can be provided by the corresponding author Damiano Caruso.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. *Eur. J. Cancer* **2013**, *49*, 1374–1403. [[CrossRef](#)]
2. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer J. Clin.* **2018**, *68*, 394–424. [[CrossRef](#)]
3. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* **2017**, *20*, 1–19. [[CrossRef](#)]
4. Smyth, E.C.; Verheij, M.; Allum, W.; Cunningham, D.; Cervantes, A.; Arnold, D.; Committee, E.G. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **2016**, *27*, v38–v49. [[CrossRef](#)] [[PubMed](#)]
5. Cunningham, D.; Allum, W.H.; Stenning, S.P.; Thompson, J.N.; Van de Velde, C.J.; Nicolson, M.; Scarffe, J.H.; Lofts, F.J.; Falk, S.J.; Iveson, T.J.; et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N. Engl. J. Med.* **2006**, *355*, 11–20. [[CrossRef](#)] [[PubMed](#)]
6. Thuss, P.; Wolfgang, F.; Jorg, T.; Michael, K.; Claudia, P.; Thorsten Oliver, G.; Elke, J.; Johannes, M.; Martin, H.S.; Ralf Hofheinz, S.-E.A.-B.; et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. *J. Clin. Oncol.* **2017**. [[CrossRef](#)]
7. Smyth, E.C.; Wotherspoon, A.; Peckitt, C.; Gonzalez, D.; Hulkki-Wilson, S.; Eltahir, Z.; Fassan, M.; Rugge, M.; Valeri, N.; Okines, A.; et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. *JAMA Oncol.* **2017**, *3*, 1197–1203. [[CrossRef](#)]
8. Petrillo, A.; Pompella, L.; Tirino, G.; Pappalardo, A.; Laterza, M.M.; Caterino, M.; Orditura, M.; Ciardiello, F.; Lieto, E.; Galizia, G.; et al. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. *Cancers* **2019**, *11*, 399. [[CrossRef](#)] [[PubMed](#)]
9. Kohlruss, M.; Grosser, B.; Krenauer, M.; Slotta-Huspenina, J.; Jesinghaus, M.; Blank, S.; Novotny, A.; Reiche, M.; Schmidt, T.; Ismani, L.; et al. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: Role of Epstein-Barr virus infection and high- and low-microsatellite instability. *J. Pathol. Clin. Res.* **2019**, *5*, 227–239. [[CrossRef](#)] [[PubMed](#)]

10. De Cecco, C.N.; Ganeshan, B.; Ciolina, M.; Rengo, M.; Meinel, F.G.; Musio, D.; De Felice, F.; Raffetto, N.; Tombolini, V.; Laghi, A. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance. *Investig. Radiol.* **2015**, *50*, 239–245. [[CrossRef](#)]
11. Yip, S.S.; Aerts, H.J. Applications and limitations of radiomics. *Phys. Med. Biol.* **2016**, *61*, R150–R166. [[CrossRef](#)]
12. Ferrari, R.; Mancini-Terracciano, C.; Voena, C.; Rengo, M.; Zerunian, M.; Ciardiello, A.; Grasso, S.; Mare, V.; Paramatti, R.; Russomando, A.; et al. MR-based artificial intelligence model to assess response to therapy in locally advanced rectal cancer. *Eur. J. Radiol.* **2019**, *118*, 1–9. [[CrossRef](#)] [[PubMed](#)]
13. Caruso, D.; Zerunian, M.; Ciolina, M.; de Santis, D.; Rengo, M.; Soomro, M.H.; Giunta, G.; Conforto, S.; Schmid, M.; Neri, E.; et al. Haralick's texture features for the prediction of response to therapy in colorectal cancer: A preliminary study. *Radiol. Med.* **2018**, *123*, 161–167. [[CrossRef](#)] [[PubMed](#)]
14. Caruso, D.; Polici, M.; Zerunian, M.; Pucciarelli, F.; Guido, G.; Polidori, T.; Landolfi, F.; Nicolai, M.; Lucertini, E.; Tarallo, M.; et al. Radiomics in Oncology, Part 1: Technical Principles and Gastrointestinal Application in CT and MRI. *Cancers* **2021**, *13*, 2522. [[CrossRef](#)] [[PubMed](#)]
15. Caruso, D.; Polici, M.; Zerunian, M.; Pucciarelli, F.; Guido, G.; Polidori, T.; Landolfi, F.; Nicolai, M.; Lucertini, E.; Tarallo, M.; et al. Radiomics in Oncology, Part 2: Thoracic, Genito-Urinary, Breast, Neurological, Hematologic and Musculoskeletal Applications. *Cancers* **2021**, *13*, 2681. [[CrossRef](#)]
16. Giganti, F.; Antunes, S.; Salerno, A.; Ambrosi, A.; Marra, P.; Nicoletti, R.; Orsenigo, E.; Chiari, D.; Albarello, L.; Staudacher, C.; et al. Gastric cancer: Texture analysis from multidetector computed tomography as a potential preoperative prognostic biomarker. *Eur. Radiol.* **2017**, *27*, 1831–1839. [[CrossRef](#)] [[PubMed](#)]
17. Li, Z.; Zhang, D.; Dai, Y.; Dong, J.; Wu, L.; Li, Y.; Cheng, Z.; Ding, Y.; Liu, Z. Computed tomography-based radiomics for prediction of neoadjuvant chemotherapy outcomes in locally advanced gastric cancer: A pilot study. *Chin. J. Cancer Res.* **2018**, *30*, 406–414. [[CrossRef](#)]
18. Giganti, F.; Marra, P.; Ambrosi, A.; Salerno, A.; Antunes, S.; Chiari, D.; Orsenigo, E.; Esposito, A.; Mazza, E.; Albarello, L.; et al. Pre-treatment MDCT-based texture analysis for therapy response prediction in gastric cancer: Comparison with tumour regression grade at final histology. *Eur. J. Radiol.* **2017**, *90*, 129–137. [[CrossRef](#)]
19. Becker, K.; Mueller, J.D.; Schulmacher, C.; Ott, K.; Fink, U.; Busch, R.; Bottcher, K.; Siewert, J.R.; Hofler, H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. *Cancer* **2003**, *98*, 1521–1530. [[CrossRef](#)]
20. Amin, M.B.; Greene, F.L.; Edge, S.B.; Compton, C.C.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.; Gress, D.M.; Byrd, D.R.; Winchester, D.P. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J. Clin.* **2017**, *67*, 93–99. [[CrossRef](#)]
21. AJCC—AJCC 8th Edition Cancer Staging Form, Histology and Topography Supplements Available Now. Available online: <https://cancerstaging.org/About/news/Pages/AJCC-8th-Edition-Cancer-Staging-Form-and-Histology-and-Topography-Supplements-Available-Now.aspx> (accessed on 28 March 2021).
22. Caruso, D.; Rosati, E.; Panvini, N.; Rengo, M.; Bellini, D.; Moltoni, G.; Bracci, B.; Lucertini, E.; Zerunian, M.; Polici, M.; et al. Optimization of contrast medium volume for abdominal CT in oncologic patients: Prospective comparison between fixed and lean body weight-adapted dosing protocols. *Insights Imaging* **2021**, *12*, 40. [[CrossRef](#)]
23. Caruso, D.; De Santis, D.; Rivosecchi, F.; Zerunian, M.; Panvini, N.; Montesano, M.; Biondi, T.; Bellini, D.; Rengo, M.; Laghi, A. Lean Body Weight-Tailored Iodinated Contrast Injection in Obese Patient: Boer versus James Formula. *Biomed. Res. Int.* **2018**, *2018*, 8521893. [[CrossRef](#)] [[PubMed](#)]
24. Caruso, D.; Zerunian, M.; Pucciarelli, F.; Bracci, B.; Polici, M.; D'Arrigo, B.; Polidori, T.; Guido, G.; Barbato, L.; Polverari, D.; et al. Influence of Adaptive Statistical Iterative Reconstructions on CT Radiomic Features in Oncologic Patients. *Diagnostics* **2021**, *11*, 1000. [[CrossRef](#)]
25. Ma, Z.; Fang, M.; Huang, Y.; He, L.; Chen, X.; Liang, C.; Huang, X.; Cheng, Z.; Dong, D.; Xie, J.; et al. CT-based radiomics signature for differentiating Borrmann type IV gastric cancer from primary gastric lymphoma. *Eur. J. Radiol.* **2017**, *91*, 142–147. [[CrossRef](#)] [[PubMed](#)]
26. van Griethuysen, J.J.M.; Fedorov, A.; Parmar, C.; Hosny, A.; Aucoin, N.; Narayan, V.; Beets-Tan, R.G.H.; Fillion-Robin, J.C.; Pieper, S.; Aerts, H. Computational Radiomics System to Decode the Radiographic Phenotype. *Cancer Res.* **2017**, *77*, e104–e107. [[CrossRef](#)]
27. Neves Filho, E.H.; de Sant'Ana, R.O.; Nunes, L.V.; Pires, A.P.; da Cunha, M.D. Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: A critical review. *APMIS* **2017**, *125*, 79–84. [[CrossRef](#)]
28. Liu, S.; Liu, S.; Ji, C.; Zheng, H.; Pan, X.; Zhang, Y.; Guan, W.; Chen, L.; Guan, Y.; Li, W.; et al. Application of CT texture analysis in predicting histopathological characteristics of gastric cancers. *Eur. Radiol.* **2017**, *27*, 4951–4959. [[CrossRef](#)] [[PubMed](#)]
29. Wang, Y.; Liu, W.; Yu, Y.; Liu, J.J.; Xue, H.D.; Qi, Y.F.; Lei, J.; Yu, J.C.; Jin, Z.Y. CT radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer. *Eur. Radiol.* **2020**, *30*, 976–986. [[CrossRef](#)]
30. Sun, K.Y.; Hu, H.T.; Chen, S.L.; Ye, J.N.; Li, G.H.; Chen, L.D.; Peng, J.J.; Feng, S.T.; Yuan, Y.J.; Hou, X.; et al. CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer. *BMC Cancer* **2020**, *20*, 468. [[CrossRef](#)] [[PubMed](#)]

31. Braman, N.M.; Etesami, M.; Prasanna, P.; Dubchuk, C.; Gilmore, H.; Tiwari, P.; Plecha, D.; Madabhushi, A. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. *Breast Cancer Res.* **2017**, *19*, 57. [[CrossRef](#)] [[PubMed](#)]
32. Ganeshan, B.; Goh, V.; Mandeville, H.C.; Ng, Q.S.; Hoskin, P.J.; Miles, K.A. Non-small cell lung cancer: Histopathologic correlates for texture parameters at CT. *Radiology* **2013**, *266*, 326–336. [[CrossRef](#)] [[PubMed](#)]
33. Mazzei, M.A.; Nardone, V.; Di Giacomo, L.; Bagnacci, G.; Gentili, F.; Tini, P.; Marrelli, D.; Volterrani, L. The role of delta radiomics in gastric cancer. *Quant. Imaging Med. Surg.* **2018**, *8*, 719–721. [[CrossRef](#)] [[PubMed](#)]